SG Americas Securities LLC Buys 52,494 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

SG Americas Securities LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 51.2% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 154,992 shares of the biopharmaceutical company’s stock after purchasing an additional 52,494 shares during the quarter. SG Americas Securities LLC’s holdings in Gilead Sciences were worth $11,353,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Metis Global Partners LLC increased its position in shares of Gilead Sciences by 3.0% during the 1st quarter. Metis Global Partners LLC now owns 61,440 shares of the biopharmaceutical company’s stock valued at $4,500,000 after purchasing an additional 1,770 shares during the last quarter. Empowered Funds LLC increased its position in shares of Gilead Sciences by 62.7% during the 1st quarter. Empowered Funds LLC now owns 195,726 shares of the biopharmaceutical company’s stock valued at $14,337,000 after purchasing an additional 75,463 shares during the last quarter. AIA Group Ltd purchased a new stake in Gilead Sciences in the 1st quarter worth approximately $1,684,000. Quantbot Technologies LP purchased a new stake in Gilead Sciences in the 1st quarter worth approximately $573,000. Finally, Envestnet Portfolio Solutions Inc. increased its holdings in Gilead Sciences by 31.8% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 112,743 shares of the biopharmaceutical company’s stock worth $8,258,000 after acquiring an additional 27,211 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. HSBC raised shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price for the company in a report on Wednesday, April 24th. StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Royal Bank of Canada reissued a “sector perform” rating and issued a $74.00 target price on shares of Gilead Sciences in a report on Monday, July 1st. Raymond James raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 target price for the company in a report on Monday, July 8th. Finally, Maxim Group dropped their price target on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Wednesday, May 1st. Twelve equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Hold” and a consensus target price of $84.00.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now directly owns 96,380 shares in the company, valued at $6,614,559.40. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Stock Down 0.0 %

NASDAQ GILD opened at $69.96 on Friday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.94 and a current ratio of 1.08. The company has a market capitalization of $87.16 billion, a P/E ratio of 194.33, a P/E/G ratio of 2.97 and a beta of 0.18. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $87.86. The stock has a 50 day moving average price of $66.43 and a 200-day moving average price of $71.74.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The company had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. Gilead Sciences’s revenue was up 5.3% on a year-over-year basis. During the same period last year, the company earned $1.37 earnings per share. As a group, equities analysts predict that Gilead Sciences, Inc. will post 3.71 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, June 27th. Investors of record on Friday, June 14th were given a $0.77 dividend. The ex-dividend date of this dividend was Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a yield of 4.40%. Gilead Sciences’s dividend payout ratio is presently 855.56%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.